Lanreotid Zentiva

Lanreotide, the active ingredient in Lanreotid Zentiva, is a somatostatin analog presented as a sterile solution for subcutaneous injection. It is used to control excess growth hormone secretion in acromegaly and to inhibit hormone‑producing neuroendocrine tumors in adult patients.

GNH USA supplies Lanreotid Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring quality‑assured product availability across regulated markets. The product complies with European Union marketing authorisation standards and is distributed under strict cold‑chain conditions.

Lanreotid Zentiva (lanreotide) is employed in the management of disorders driven by excess growth hormone or peptide hormone secretion.

Acromegaly: reduces serum IGF‑1 levels and controls disease activity. Neuroendocrine tumors (e.g., carcinoid): alleviates hormone‑related symptoms and may slow tumor progression. VIPoma: suppresses vasoactive intestinal peptide secretion, improving diarrhoea and electrolyte balance.

Lanreotid Zentiva may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Injection site pain or erythema - Nausea or vomiting - Diarrhoea or abdominal cramps - Headache - Hyperglycaemia or altered glucose tolerance - Fatigue

Serious or Rare Side Effects: - Gallstone formation or biliary colic - Acute pancreatitis - Severe allergic reactions (anaphylaxis, angio‑edema) - Cardiac arrhythmias - Pituitary apoplexy in patients with pre‑existing adenomas - Severe hepatic dysfunction

Before initiating therapy, clinicians should consider several safety aspects.

Monitor glucose levels: assess for hyperglycaemia, especially in diabetic patients. Assess gallbladder status: evaluate for gallstones or biliary disease prior to treatment. Evaluate pituitary tumor size: watch for signs of apoplexy in acromegaly patients. Adjust dose in hepatic or renal impairment: use caution and consider dose modification. Avoid in known hypersensitivity: discontinue if allergic reaction occurs. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Octreotide: additive suppression of hormone secretion may lead to excessive hormonal inhibition. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lanreotide plasma concentrations. - Cyclosporine: elevated lanreotide levels can enhance adverse effects.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: monitor blood glucose as lanreotide may affect glycaemic control. - Anticoagulants: observe for altered bleeding risk. - Diuretics: watch electrolyte balance, especially potassium. - Other peptide hormone therapies: assess for overlapping pharmacodynamic effects.